Table 1.
Baseline and clinical characteristics of the included patients
|
Characteristics
|
TDs+LNM-(n = 89) |
LNM+TDs– (n = 115) |
P
value
|
Training set (n = 163) |
Validation set (n = 41) |
P
value
|
| Age (mean ± SD, yr) | 59 ± 12 | 61 ± 12 | 0.268 | 60 ± 12 | 60 ± 11 | 0.965 |
| Gender (man/woman) | 49/40 | 63/52 | 0.969 | 94/69 | 18/23 | 0.113 |
| Location (middle-low/high) | 65/24 | 74/41 | 0.187 | 107/56 | 32/9 | 0.128 |
| Neoadjuvant therapy (+/-) | 34/55 | 43/72 | 0.906 | 62/101 | 15/26 | 0.864 |
| CEA (+/-) (positive ≥ 5 ng/mL) | 42/47 | 43/72 | 0.159 | 75/88 | 10/31 | 0.012 |
| CA19-9 (+/-) (positive ≥ 30 U/mL) | 23/66 | 18/97 | 0.072 | 34/129 | 7/34 | 0.589 |
| CA125 (+/-) (positive ≥ 24 U/mL) | 13/76 | 14/101 | 0.611 | 21/142 | 6/35 | 0.767 |
| pT stage (T1/T2/T3/T4) | 0/9/70/10 | 4/12/93/6 | 0.063 | 4/17/127/15 | 0/4/36/1 | 0.894 |
| pN stage (1a/1b/1c/2a/2b) | 0/0/89/0/0 | 52/39/0/15/9 | < 0.001 | 37/33/71/13/9 | 15/6/18/2/0 | 0.115 |
| Histologic EMVI (+/-) | 33/56 | 16/99 | < 0.001 | 41/122 | 8/33 | 0.450 |
| Histologic grade (G1/G2/G3) | 1/63/25 | 0/76/39 | 0.299 | 0/113/50 | 1/26/14 | 0.901 |
| Peritumoral nodule | ||||||
| Shape (irregular/regular) | 12/77 | 2/113 | 0.003 | 11/152 | 3/38 | 0.898 |
| Spiculation (+/-) | 7/82 | 2/113 | 0.077 | 7/156 | 2/39 | 0.871 |
| Size (mm2) (median) | 72.7 | 41.2 | < 0.001 | 54 | 43 | 0.886 |
| CT value (HU) | 61 ± 22 | 65 ± 23 | 0.258 | 64 ± 23 | 63 ± 23 | 0.858 |
| Rad-score 1 (median) | 0.71 | 0.39 | < 0.001 | 0.44 | 0.71 | 0.002 |
| Rad-score 2 (median) | 0.89 | 0.13 | < 0.001 | 0.39 | 0.62 | 0.561 |
Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; CT: Computed tomography; TDs: Tumor deposits; LNM: Lymph node metastasis; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; pT stage: Pathological T stage; pN stage: Pathological N stage; EMVI: Extramural vascular invasion.